Beaton Management Co. Inc. Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)

Beaton Management Co. Inc. lessened its position in Johnson & Johnson (NYSE:JNJ) by 0.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 21,927 shares of the company’s stock after selling 207 shares during the period. Johnson & Johnson makes up 1.6% of Beaton Management Co. Inc.’s investment portfolio, making the stock its 20th largest holding. Beaton Management Co. Inc.’s holdings in Johnson & Johnson were worth $3,171,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Atria Wealth Solutions Inc. grew its stake in shares of Johnson & Johnson by 1.7% during the 4th quarter. Atria Wealth Solutions Inc. now owns 162,782 shares of the company’s stock worth $23,542,000 after purchasing an additional 2,784 shares during the period. Kornitzer Capital Management Inc. KS boosted its holdings in Johnson & Johnson by 1.5% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 349,105 shares of the company’s stock worth $50,488,000 after buying an additional 5,251 shares in the last quarter. Mraz Amerine & Associates Inc. grew its position in Johnson & Johnson by 38.9% during the fourth quarter. Mraz Amerine & Associates Inc. now owns 24,118 shares of the company’s stock worth $3,488,000 after buying an additional 6,760 shares during the period. Venturi Wealth Management LLC increased its holdings in Johnson & Johnson by 61.7% in the fourth quarter. Venturi Wealth Management LLC now owns 19,662 shares of the company’s stock valued at $2,843,000 after buying an additional 7,502 shares in the last quarter. Finally, Citizens & Northern Corp lifted its position in shares of Johnson & Johnson by 14.7% during the 4th quarter. Citizens & Northern Corp now owns 2,555 shares of the company’s stock valued at $370,000 after acquiring an additional 327 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.1 %

Shares of NYSE:JNJ opened at $159.62 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a 50-day simple moving average of $148.61 and a 200-day simple moving average of $155.89. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a market capitalization of $384.29 billion, a P/E ratio of 24.00, a PEG ratio of 2.49 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.29 earnings per share. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.11%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Analyst Upgrades and Downgrades

A number of research firms have commented on JNJ. Stifel Nicolaus lowered their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Citigroup lowered their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Barclays lifted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Raymond James lowered their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Finally, Bank of America cut their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.